Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.59 |
| ▸ | EYA2 | O00167 | 1/20 | 0.59 |
| ▸ | APP | P05067 | 1/20 | 0.59 |
| ▸ | ACE | P12821 | 1/20 | 0.59 |
| ▸ | BLM | P54132 | 3/20 | 0.56 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | TSHR | P16473 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.56 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
| ▸ | DRD1 | P21728 | 1/20 | 0.56 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.56 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.56 |
| ▸ | DRD3 | P35462 | 1/20 | 0.56 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.56 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1395267 | 0.98 | TDP1 (0.56) | TDP1EYA2APPACEBLM | |
| SCHEMBL6428959 | 0.96 | TDP1 (0.54) | TDP1EYA2APPACEBLM | |
| SCHEMBL2241682 | 0.93 | TDP1 (0.64) | TDP1EYA2APPACEBLM | |
| SCHEMBL1395023 | 0.93 | TDP1 (0.64) | TDP1EYA2APPACEBLM | |
| SCHEMBL6427963 | 0.91 | TDP1 (0.61) | TDP1EYA2APPACEBLM | |
| SCHEMBL6428138 | 0.91 | TDP1 (0.61) | TDP1EYA2APPACEBLM | |
| SCHEMBL67368 | 0.90 | TDP1 (0.50) | TDP1EYA2APPACEBLM | |
| SCHEMBL27709276 | 0.90 | TDP1 (0.50) | TDP1EYA2APPACEBLM | |
| SCHEMBL65674 | 0.90 | TDP1 (0.50) | TDP1EYA2APPACEBLM | |
| SCHEMBL11895837 | 0.90 | TDP1 (0.50) | TDP1EYA2APPACEBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170239182-A1 | PHARMACEUTICAL FORMULATIONS OF AND METHODS TO PREPARE CHELATING AGENTS FOR EFFICIENT METAL REMOVAL TREATMENT SYSTEMS | HAYES MARK E (US) | 2017-08-24 | — | — | US | claimed |
| US-20170231910-A1 | PHARMACEUTICAL FORMULATIONS OF CHELATING AGENTS AS A METAL REMOVAL TREATMENT SYSTEM | HAYES MARK E (US) | 2017-08-17 | — | — | US | claimed |
| US-20140271825-A1 | PHARMACEUTICAL FORMULATIONS OF CHELATING AGENTS AS A METAL REMOVAL TREATMENT SYSTEM | ZONEONE PHARMA, INC. | 2014-09-18 | — | — | US | claimed |
| US-11766441-B2 | Oral liquid compositions including chlorpromazine | Genus Lifesciences Inc. (US) | 2023-09-26 | — | — | US | disclosed |
| EP-4221714-A1 | ORAL LIQUID COMPOSITIONS INCLUDING CHLORPROMAZINE | Genus Lifesciences Inc. (US) | 2023-08-09 | — | — | EP | disclosed |
| US-20170239182-A1 | PHARMACEUTICAL FORMULATIONS OF AND METHODS TO PREPARE CHELATING AGENTS FOR EFFICIENT METAL REMOVAL TREATMENT SYSTEMS | HAYES MARK E (US) | 2017-08-24 | — | — | US | disclosed |
| US-20170231910-A1 | PHARMACEUTICAL FORMULATIONS OF CHELATING AGENTS AS A METAL REMOVAL TREATMENT SYSTEM | HAYES MARK E (US) | 2017-08-17 | — | — | US | disclosed |
| US-20170128366-A1 | PHARMACEUTICAL FORMULATIONS OF CHELATING AGENTS AS A METAL REMOVAL TREATMENT SYSTEM | ZONEONE PHARMA INC (US) | 2017-05-11 | — | — | US | disclosed |
| WO-2016025559-A1 | PHARMACEUTICAL FORMULATIONS OF AND METHODS TO PREPARE CHELATING AGENTS FOR EFFICIENT METAL REMOVAL TREATMENT SYSTEMS | ZONEONE PHARMA, INC. (US) | 2016-02-18 | — | — | WO | disclosed |
| WO-2016025611-A2 | PHARMACEUTICAL FORMULATIONS OF CHELATING AGENTS AS A METAL REMOVAL TREATMENT SYSTEM | ZONEONE PHARMA, INC. (US) | 2016-02-18 | — | — | WO | disclosed |
| US-20140271825-A1 | PHARMACEUTICAL FORMULATIONS OF CHELATING AGENTS AS A METAL REMOVAL TREATMENT SYSTEM | ZONEONE PHARMA, INC. | 2014-09-18 | — | — | US | disclosed |
| US-5068404-A | Heating aqueous solution of di- or tri-alkali metal salt of N-alkyl-N-phosphonomethylglycine | MONSANTO COMPANY (US) | 1991-11-26 | — | — | US | disclosed |
| EP-0187633-B1 | THERMAL DEALKYLATION OF N-ALKYL N-PHOSPHONOMETHYLGLYCINE | Monsanto Company (US) | 1989-03-01 | — | — | EP | disclosed |
| EP-0187633-A1 | Thermal dealkylation of n-alkyl n-phosphonomethylglycine | Monsanto Company (US) | 1986-07-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11766441-B2 | Oral liquid compositions including chlorpromazine | WIZ, CPNE4, CYP3A5 | TDP1 1178/4885EYA2 2984/4885APP 4110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.